Posted by Michael Wonder on 25 Nov 2020
Merck racks up another NICE recommendation for Keytruda
25 November 2020 - That makes it number 12.
Pembrolizumab is recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a combined positive score of 1 or more.
This is only if:
- Pembrolizumab is given as a monotherapy
- Pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
- Merck provides pembrolizumab according to the commercial arrangement.
Read NICE final technology guidance for pembrolizumab
Posted by:
Michael Wonder